Vulvar Cancer

News alerts, weekly reports and conference planners

PD-L1 expression	Vulvar Cancer	PD-L1 expression	Vulvar Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
NTRK3 fusion	Vulvar Cancer	NTRK3 fusion	Vulvar Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Vulvar Cancer	NTRK2 fusion	Vulvar Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Vulvar Cancer	NTRK1 fusion	Vulvar Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion	Vulvar Cancer	NTRK3 fusion	Vulvar Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Vulvar Cancer	NTRK2 fusion	Vulvar Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Vulvar Cancer	NTRK1 fusion	Vulvar Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
MSI-H/dMMR	Vulvar Cancer	MSI-H/dMMR	Vulvar Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Vulvar Cancer	TMB-H	Vulvar Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	5-fluorouracil + mitomycin Sensitive: A2 - Guideline 5-fluorouracil + mitomycin Sensitive : A2	5-fluorouracil + mitomycin Sensitive: A2 - Guideline 5-fluorouracil + mitomycin Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	capecitabine + mitomycin Sensitive: A2 - Guideline capecitabine + mitomycin Sensitive : A2	capecitabine + mitomycin Sensitive: A2 - Guideline capecitabine + mitomycin Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
PD-L1 negative	Vulvar Cancer	PD-L1 negative	Vulvar Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
PD-L1 overexpression	Vulvar Cancer	PD-L1 overexpression	Vulvar Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4

Vulvar Cancer

Associations(24)

Associations
(24)